Thyrocare Technologies Ltd (IN:THYROCARE)
:THYROCARE
THYROCARE Stock Chart & Stats
₹459.10
-₹16.20(-1.70%)
At close: 4:00 PM EST
₹459.10
-₹16.20(-1.70%)
Day’s Range― - ―
52-Week Range₹220.02 - ₹537.97
Previous CloseN/A
Volume114.81K
Average Volume (3M)56.30K
Market Cap
₹55.67B
Enterprise Value₹18.08B
Total Cash (Recent Filing)₹1.92B
Total Debt (Recent Filing)₹246.80M
Price to Earnings (P/E)61.2
Beta0.49
Next Earnings
May 21, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield0.68%
Share Statistics
EPS (TTM)4.30
Shares Outstanding159,165,310
10 Day Avg. Volume44,587
30 Day Avg. Volume56,302
Financial Highlights & Ratios
PEG Ratio0.49
Price to Book (P/B)2.35
Price to Sales (P/S)1.87
P/FCF Ratio8.78
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)10.1
Revenue Forecast (FY)₹8.17B
Bulls Say, Bears Say
Bulls Say
Revenue & EPS GrowthSustained top-line growth (≈21% recent revenue growth) combined with strong EPS expansion indicates durable demand for testing services and improving operating leverage. This trend supports reinvestment capacity and long-term margin recovery as volumes scale across centralized labs.
Scalable Centralized Lab ModelA centralized, automated lab footprint with a broad diagnostic menu and extensive collection network creates scale-driven cost advantages and consistent throughput. This structural model supports low incremental cost per test, higher utilization, and defensible unit economics over multiple quarters.
Strong Cash GenerationRising operating cash flow and positive free cash flow growth point to high-quality earnings and internal funding for capex and expansions. Consistent cash conversion reduces reliance on external financing and enhances resilience to cyclical demand shifts over the medium term.
Bears Say
Pressure On Net MarginsA slight decline in net profit margin suggests rising operating costs or financial expenses that could erode returns if persistent. Without margin stabilization, higher volumes may not translate fully into bottom-line improvement, limiting long-term profitability expansion.
Significant Capital ExpenditureOngoing sizable capex reduces near-term free cash flow and can constrain liquidity if demand softens. Continued heavy investment is needed to maintain automation and capacity, but it also raises execution and funding risk over the medium term if returns on that capex slow.
Small Increase In Total DebtAlthough leverage remains low overall, a recent uptick in total debt modestly raises financial risk and reduces excess balance-sheet flexibility. If debt rises further or cash generation weakens, refinancing or interest costs could pressure earnings and capital allocation choices.
Thyrocare Technologies Ltd News
THYROCARE FAQ
What was Thyrocare Technologies Ltd’s price range in the past 12 months?
Thyrocare Technologies Ltd lowest stock price was ₹220.02 and its highest was ₹537.97 in the past 12 months.
What is Thyrocare Technologies Ltd’s market cap?
Thyrocare Technologies Ltd’s market cap is ₹55.67B.
When is Thyrocare Technologies Ltd’s upcoming earnings report date?
Thyrocare Technologies Ltd’s upcoming earnings report date is May 21, 2026 which is in 51 days.
How were Thyrocare Technologies Ltd’s earnings last quarter?
Thyrocare Technologies Ltd released its earnings results on Jan 28, 2026. The company reported ₹4.3 earnings per share for the quarter, missing the consensus estimate of ₹4.5 by -₹0.2.
Is Thyrocare Technologies Ltd overvalued?
According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued.
Does Thyrocare Technologies Ltd pay dividends?
Thyrocare Technologies Ltd pays a Quarterly dividend of ₹2.333 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here
What is Thyrocare Technologies Ltd’s EPS estimate?
Thyrocare Technologies Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Thyrocare Technologies Ltd have?
Thyrocare Technologies Ltd has 159,165,310 shares outstanding.
What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?
Thyrocare Technologies Ltd reported an EPS of ₹4.3 in its last earnings report, missing expectations of ₹4.5. Following the earnings report the stock price went up 1.313%.
Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?
Currently, no hedge funds are holding shares in IN:THYROCARE
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Thyrocare Technologies Ltd
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates in three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, COVID, and various infectious diseases. Its profiles of tests include 34 profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company also sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
Technical Analysis
Krsnaa Diagnostics Limited
―
Medi Assist Healthcare Services Limited
―
Metropolis Healthcare Ltd.
―
Morepen Laboratories Limited
―
Vijaya Diagnostic Centre Ltd.
―